Johnson Massey, MD
Cardiovascular Disease · Kissimmee, FLNPI 1265432231
Payments from drug & device makers
Across 92 payments — averaging $15.68 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Kestra Medical Technology Services, Inc.$207
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$189
- Johnson & Johnson$164
- Alnylam Pharmaceuticals Inc.$102
- Merck$95
- Novartis$88
- plus $597 from 14 others
What the payments were for
- Food & beverage$1,40798%
- Education$362%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Kestra Medical Technology Services, Inc. | 6 | $207 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 29 | $189 |
| Johnson & Johnson | 9 | $164 |
| Alnylam Pharmaceuticals Inc. | 4 | $102 |
| Merck | 6 | $95 |
| Novartis | 5 | $88 |
| Amgen | 6 | $86 |
| Cvrx, Inc. | 3 | $73 |
| E.r. Squibb & Sons, L.L.C. | 4 | $66 |
| Esperion Therapeutics, Inc. | 3 | $64 |
| Boehringer Ingelheim | 3 | $64 |
| Impulse Dynamics (USA) Inc. | 3 | $63 |
| AstraZeneca | 4 | $58 |
| Kiniksa Pharmaceuticals, Ltd. | 1 | $21 |
| Novo Nordisk | 1 | $21 |
| Inspire Medical Systems, Inc. | 1 | $21 |
| Abiomed | 1 | $18 |
| Astellas Pharma US Inc | 1 | $16 |
| Pfizer | 1 | $14 |
| Abbott | 1 | $12 |
How this compares
$1,442 in reported general payments places this provider in the 30th percentile of 1,740 cardiovascular disease providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 418 | $442,888 |
| EntrestoSacubitril/Valsartan | 144 | $177,836 |
| XareltoRivaroxaban | 61 | $82,467 |
| JardianceEmpagliflozin | 63 | $55,521 |
| FarxigaDapagliflozin Propanediol | 51 | $51,373 |
| Repatha SureclickEvolocumab | 50 | $37,447 |
| BrilintaTicagrelor | 23 | $16,194 |
| Metoprolol Succinate | 602 | $10,711 |
| Rosuvastatin Calcium | 477 | $5,892 |
| Ranolazine ErRanolazine | 48 | $5,688 |
| Losartan Potassium | 492 | $4,399 |
| Ezetimibe | 161 | $3,472 |
| Dabigatran EtexilateDabigatran Etexilate Mesylate | 18 | $3,356 |
| Carvedilol | 343 | $3,170 |
| Amiodarone Hcl | 68 | $2,942 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $14 | $442,888418 claims |
| NovartisEntresto | $88 | $177,836144 claims |
| Johnson & JohnsonXarelto | $164 | $82,46761 claims |
| AstraZenecaFarxiga, Brilinta | $58 | $67,56774 claims |
| Boehringer IngelheimJardiance | $64 | $55,52163 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 30th percentile of 1,740 cardiovascular disease providers in Florida.
Other cardiovascular disease in Kissimmee
- Michael KorenGainesville$31M
- Seth BaumBoca Raton$11.1M
- Alexis GutierrezHialeah$8M
- Eric SpivackAventura$7.1M
- William OneillNaples$4.6M
- Rafik AbadierInverness$4.4M
- Alvaro MurciaPembroke Pines$4M
- David HotchkissPort Charlotte$4M
- Ferris GeorgeSt Augustine$3.8M
- Duccio BaldariWellington$3.5M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.